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Local overexpression of C-type natriuretic peptide ameliorates
vascular adaptation of porcine hemodialysis grafts.
Background. Outflow obstruction at the outflow tract of ar-
teriovenous grafts contributes significantly to the poor patency
rates of dialysis grafts in vivo. We addressed the potential of
local periadventitial gene therapy at the outflow tract for im-
proving access patency in a validated porcine model of arte-
riovenous grafts using an adenoviral vector encoding murine
C-type natriuretic peptide (Ad.CNP).
Methods. Gene transfer efficiency and optimal virus con-
centration were determined using Ad.LacZ on porcine jugu-
lar veins in vivo (N = 2). Next, in 14 pigs, arteriovenous grafts
were implanted bilaterally between the carotid artery and the
jugular vein, followed local venous transduction with Ad.CNP
(right) and Ad.mock (left). Transduction efficiency of Ad.CNP
was evaluated by reverse transcription-polymerase chain reac-
tion (RT-PCR) and cyclic guanosine monophosphate (cGMP)
measurements (N = 2). Fourteen days after gene transfer, arte-
riovenous grafts were excised for histologic analysis (N = 12).
Results. Ad.LacZ transduction (1 × 10E10 IU) of porcine
veins resulted in evident expression of b-galactosidase, mainly
in the adventitia. At termination, intima/media ratio was de-
creased by 37% in CNP-treated veins, predominantly due to
medial thickening (Ad.CNP 3.1 ± 0.6 mm2 vs. Ad.mock 1.70 ±
0.3 mm2; P < 0.01) rather than decreased intimal hyperplasia
(NS). Adventitial delivery of CNP resulted in increased exter-
nal elastic lamina (EEL) (Ad.CNP 11.8 ± 1.4 mm vs. Ad.mock
9.4 ± 1.0 mm; P = 0.04) and luminal area (Ad.CNP 10.7 ±
1.4 mm2 vs. Ad.mock 8.8 ± 1.7 mm2; P = 0.05) at the venous
anastomosis.
Conclusion. Overexpression of CNP enhances venous me-
dial thickening and increases outward remodeling in the outflow
tract of porcine arteriovenous grafts. These findings underscore
the potential of local gene-therapeutic interventions in prevent-
ing luminal narrowing at the outflow tract of hemodialysis grafts.
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Hemodialysis access complications constitute a major
cause of morbidity in hemodialysis patients. In the United
States, approximately 70% of the 230,000 hemodialysis
patients depend upon an expanded polytetrafluoroethy-
lene (ePTFE) graft for permanent vascular access. The
current 1- and 2-year primary patency rates of ePTFE
grafts are as low as 50% and 25%, respectively [1]. The
failure of hemodialysis access grafts is predominantly due
to flow impairment at the venous outflow tract, predom-
inantly due to the rapid development of an intimal hy-
perplastic response in a localized region at the venous
anastomosis [2]. This intimal hyperplasia is characterized
by vascular smooth muscle cells (VSMCs), microvessel
formation, and matrix deposition [3, 4]. Recent studies
have elegantly demonstrated the pivotal role of adven-
titia, and in particular the periadventitial fibroblasts as
active participants in the process of vascular remodeling
and neointima formation [5, 6]. Unfortunately, no effec-
tive measures have been reported to be able to improve
the poor patency rates of ePTFE arteriovenous grafts
[1].
C-type natriuretic peptide (CNP) is the most recently
identified member of the natriuretic peptide family [7].
CNP is an endothelium-derived peptide that binds to the
transmembrane receptor natriuretic peptide receptor-B
(NPR-B) [8], resulting in the synthesis of cyclic guanosine
monophosphate (cGMP) [9]. CNP has been shown to in-
hibit the migration of VSMC [10], constrictive remodel-
ing [11], and inhibits thrombus formation after vascular
injury [12]. In this respect, CNP has emerged as a novel
regulator of vascular tone and growth.
Intimal hyperplasia often constitutes a localized ab-
normality, which is difficult to inhibit using systemic ap-
proaches. Previously, pretreatment of the vessel (e.g.,
oligodenucleotides or adenoviral transduction) have
proven valuable in preventing intimal hyperplasia [13,
14]. More recently, Khurana et al [15] have described
paintbrush-assisted, periadventitial gene delivery as an
easily applicable, promising method for localized vascular
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use, which offers a feasible intervention during vascular
surgical procedures.
In the present study, we validated the anti-migratory ef-
fects of CNP in porcine fibroblasts in vitro. Subsequently,
we evaluated the feasibility and transduction efficiency of
localized paintbrush-assisted, periadventitial adenoviral
vector gene therapy at the venous outflow tract of arteri-
ovenous ePTFE-grafts in pigs. Finally, we compared the
composition of the venous outflow tract of either ade-
noviral vector encoding CNP (Ad.CNP) or Ad.mock-
transduced vessels.
METHODS
Vein fibroblasts isolation and culture
Fibroblasts were isolated from the epigastric vein of
Landrace pigs. After excision under sterile conditions,
the adventitia was stripped from the media with two
tweezers and finely minced. The adventitial fragments
were digested overnight at 37◦C in 6 mL of phosphate-
buffered saline (PBS) containing 30 mg of collagenase
A (Roche, Basel, Switzerland). After centrifuging the
suspension at 1500 rpm for 5 minutes, collagenase was
removed and replaced by Dulbecco’s modified Eagle’s
medium (DMEM) (Gibco, Carlsbad, CA, USA) contain-
ing 10% fetal calf serum (FCS), 25 mmol/L HEPES, peni-
cillin (100 U/mL), and streptomycin (100 lg/mL). Cells
were grown in a humidified atmosphere of 5% CO2/95%
air at 37◦C. Fibroblasts at the 3rd-5th passage were used
in the present study.
Construction and purification of recombinant adenovirus
To construct a recombinant adenovirus, cDNA of
murine CNP was inserted into the HindIII and EcoRI
sites of a cytomegalovirus (CMV) promoter containing
adenoviral shuttle vector based on adenovirus serotype
5 (AdApt.mCNP). The CNP cDNA-containing vector
was cotransfected with a cosmid vector containing the
remaining part of the Ad5 genome into PER.C6TM cells.
The recombinant virus (Ad.CNP) was produced intracel-
lularly and subsequently purified via plaques and CsCl
ultracentrifugation. Similarly, adenoviral constructs and
viral vectors carrying b-galactosidase DNA (Ad.LacZ) or
without insert (Ad.mock) were generated as described
[16]. Procedures and handling of tissues exposed to re-
combinant vectors were approved by the National Insti-
tute for Genetic Modified Organisms.
Fibroblast transduction
Subconfluent porcine fibroblasts in 6-wells plates were
transduced with Ad.CNP or Ad.mock at a multiplicity of
infection (MOI) of 500 in DMEM containing 2% FCS.
After overnight incubation, the culture medium was re-
placed by DMEM containing 10% FCS. Three days af-
ter transduction, 5 × 10−4 mol/L isobutylmethylxanthine
(IBMX) (Sigma Chemical Co., St. Louis, MO, USA) was
added to the culture medium to block phosphodiesterase
activity. The cells were incubated for additional 30 min-
utes at 37◦C. The cells were then homogenized in lysis
buffer [0.1% sodium dodecyl sulfate (SDS), 1% Triton
in PBS] for cGMP measurements, or in Tripure Isolation
Reagent (Roche, Basel, Switzerland) for RNA isolation.
Migration assay
To investigate the effect of CNP-22 (the biologically
active form of CNP on migration of porcine vein fibrob-
lasts), a Boyden chamber assay was performed using a
24-well chemotaxis chamber containing polycarbonate
filters with 8 lm pore size (Costar Corp., Cambridge, MA,
USA). Therefore, cultured fibroblasts were trypsinized
and suspended at a concentration of 5.0 × 105 cells/mL. A
volume of 100 uL of fibroblast suspension and 10−7 mol/L
human CNP-22 (American Peptide Company, Sunny-
vale, CA, USA) were placed in the upper compartment
and 600 lL of medium supplemented with 5% FCS as
chemoattractant was placed in the lower compartment.
After 8 hours of incubation, the filters were removed,
and the number of cells migrating to the lower surface
of the filter was evaluated microscopically by count-
ing the number of stained nuclei per high-power field
(×100). The same experiment was performed using
Ad.CNP (MOI 500)-transduced fibroblasts, 3 days af-
ter transduction. Ad.mock-transduced fibroblasts were
used as a control. Three independent experiments were
performed in quadruple, and each sample was counted
randomly in four different areas in the center of the mem-
brane. Migration activity was calculated as the mean num-
ber of migrated cells observed in four high power fields.
Protocol in vivo experiments
This study was approved by the ethical committee on
Animal Experimentation of the University Medical Cen-
ter Utrecht and conforms with the Guide for the Care and
Use of Laboratory Animals published by the U.S. Na-
tional Institutes of Health (NIH Publication No. 85-23,
1996). The experimental protocol is shown in Figure 1.
For this study, 16 specified pathogen-free (SPF) fe-
male Landrace pigs were used. Transduction efficiency
and optimal virus concentration were determined using
Ad.LacZ on jugular veins (N = 2). Next, in 14 pigs, ar-
teriovenous grafts were implanted bilaterally between
the carotid artery and the jugular vein, followed by in
vivo gene transfer. These pigs were transduced with
Ad.CNP (right venous anastomosis) and Ad.mock (left
venous anastomosis). Biologic activity of CNP was eval-
uated by cGMP measurements combined with reverse
transcription-polymerase chain reaction (RT-PCR),
3 days after transduction (N = 2). Histologic examination
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Fig. 1. Experimental protocol. The amount of virus applied to the jugular vein is expressed in infectious units (IU). Abbreviations are: AV,
arteriovenous; Ad.CNP, adenoviral vector encoding murine C-type natriuretic peptide; b-gal, b-galactosidase; RT-PCR, reverse transcription-
polymerase chain reaction; RIA, radioimmunoassay.
was performed in the remaining 12 pigs, 14 days after gene
transfer.
Arteriovenous graft implantation and adenoviral
transduction of porcine jugular veins
Starting 6 days before the operation, all pigs received
acetylsalicylic acid 80 mg/day. Clopidogrel 225 mg was
added 1 day prior to operation and continued at a dose of
75 mg/day until termination. ePTFE arteriovenous grafts
were created bilaterally between the carotid artery and
the internal jugular vein in 14 pigs, weighing 54 kg ±
0.9 kg, as previously described [17]. In short, through a
longitudinal incision in the midline of the neck, the com-
mon carotid artery and the internal jugular vein were
dissected bilaterally. The artery was clamped with atrau-
matic clamps and an arteriotomy was made. An end-to-
side anastomosis was created at an angle of 45◦ by use
of a continuous suture of 8–0 polypropylene (Prolene;
Ethicon, Somerville, NJ, USA). All ringed ePTFE-grafts
were 5 mm in diameter and 7 cm in length (W.L. Gore &
Associates, Flagstaff, AZ, USA). The venous anastomo-
sis was created in a similar fashion. After finishing both
anastomoses, adenoviral transduction was performed us-
ing a small synthetic paintbrush with a flat-tip diameter of
0.25 inch. Viruses were applied, 30 minutes after incuba-
tion in 37◦C water bath to improve transduction efficiency
[18]. The vectors were applied directly to the outer venous
surface at the venous anastomosis by lightly brushing the
50 lL vector solution containing 1 × 1010 IU into the
tissue [15].
Tissue preparation and histologic analysis
Two weeks after the procedure, blood flow through the
proximal and distal vein was measured with a perivascular
flow probe (Transonic Systems, Ithaca, NY, USA). Next,
grafts were perfused with formalin at physiologic pres-
sure (100 mm Hg). After 2 minutes, both sides of the ar-
teries and veins were ligated allowing pressure fixation of
the vessels. Subsequently, grafts and adjacent vessels were
excised and immersed in formalin for at least 24 hours.
The fixated veins were cut in 5 mm blocks and embedded
in paraffin. Five micrometer thick sections were prepared
of the vein 1 cm proximal and distal to the anastomosis
and at the center of the anastomosis. For morphomet-
ric analysis, sections were stained for general morphol-
ogy (Elastin von Gieson). With the highest magnification
that allowed visualization of the entire vein section in one
field, the area and thickness of the intima and media, and
the luminal area of the venous anastomosis, were manu-
ally traced. The circumference of the venous part of the
anastomosis was determined by tracing the length of the
external elastic lamina (EEL).
For immunohistochemical analysis, sections were in-
cubated in 1.5% hydrogen peroxide in methanol to
block endogenous peroxides. Next, sections were incu-
bated in boiling 10 mmol/L citrate acid for 15 minutes
and subsequently preincubated with 10% horse serum
(Vector Laboratories, Burlingame, CA, USA). Serial
sections from each graft were stained with antibodies
against a-smooth muscle actin, at 1:1500 dilution (Sigma
Chemical Co.), and Ki-67 for cellular proliferation, at
1:100 dilution (Immunotech, Marseille, France). Subse-
quently, sections were incubated with a biotinylated anti
mouse IgG antibody (Vector Laboratories) for 1 hour.
Immunoreactive materials were visualized by the use
of streptavidin-labeled horseradish peroxidase (HRPO),
diaminobenzidine in 0.05 mol/L Tris-Cl mixed with 0.01
mol/L imidazole, and 0.1% hydrogen peroxide. Sections
were counterstained with hematoxylin. A proliferation
index was defined as the number of positive cells divided
by the sum of Ki-67 negative and positive cells and ex-
pressed as a percentage.
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Apoptotic cells were detected by the terminal de-
oxynucleotidyl transferase-mediated deoxyuridine
triphosphate (dUTP)-biotin nick end labeling (TUNEL)
method by using an in situ cell death kit (Roche).
Radioimmunoassay cGMP
To examine biological activity of CNP after Ad.CNP
transduction, cGMP levels were determined using a
Radioimmunoassay Kit with 125I-labeled cGMP (Amer-
sham International, Buckinghamshire, UK). Therefore,
cultured fibroblasts were homogenized in 0.5 mL lysis
buffer containing 0.1% SDS, and 1% Triton in PBS. For
detection of cGMP levels, 3 days after in vivo gene trans-
fer, the transduced grafted veins (1 cm) were frozen in
liquid nitrogen and ground using a pestle and mortar.
cGMP extraction was performed according to manufac-
turer’s protocol.
RNA isolation and RT-PCR
Total RNA was isolated from cultured fibroblasts and
grafted veins using 1 mL Tripure Isolation Reagent
(Roche) according to manufacturer’s protocol.
Prior to the cDNA synthesis for the RT-PCR assay,
250 ng of RNA was treated with DNase to remove aden-
oviral DNA from the samples. PCR was performed with
reactions carried out for 35 cycles of 94◦C denaturation
for 30 seconds, 54,2◦C annealing for 30 seconds, and 72◦C
elongation for 30 seconds. PCR primers that only recog-
nize murine CNP sequences were used to detect ade-
noviral transferred CNP synthesis. Each reaction con-
tained 14 lL cDNA, 200 lmol/L dioxynucleoside triphos-
phate (dNTP), reaction buffer, 2.5 U Taq DNA poly-
merase and 1 lmol/L of each primer. Aliquots of each
PCR reaction mixture were size-fractionated by agarose
gel electrophoresis. The amount of b-actin mRNA was
used as a positive control for cDNA synthesis. The fol-
lowing oligonucleotides were used as primers: murine
CNP (forward primer 5′-TACAAAGGCGGCAACA
AG-3′, reverse primer 5′-GCAATAAACAAGTTCGG
ATCTC-3′) and porcine b-actin (forward primer 5′-
ACCACCTTCAACTCGATCATG-3′, reverse primer
5′-GTGATCTCCTTCTGCATCCTG-3′).
Statistical evaluation
Data are presented as mean ± standard error of the
mean. SPSS 11.0 was used for all statistical calculations.
To ascertain the significance of differences we performed
the Wilcoxon test. P values < 0.05 were considered
significant.
1 2 3 4 5 6
140 bp
β-actin
Fig. 2. Gene expression 3 days after transduction with adenoviral vec-
tor encoding murine C-type natriuretic peptide (Ad.CNP) or Ad.mock,
analyzed by reverse transcription-polymerase chain reaction (RT-
PCR). Left panel shows gene expression in cultured porcine fibroblasts.
(lanes 1 and 2, Ad.mock-transduced fibroblasts; lanes 3 and 4, Ad.CNP-
transduced fibroblasts). Right panel shows the gene expression after in
vivo gene transfer (lane 5, Ad.mock-transduced vein; lane 6, Ad.CNP-
transduced vein). The amount of b-actin mRNA was used as internal
standards.
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Fig. 3. Effect of C-type natriuretic peptide (CNP)-22 and adenoviral
vector encoding murine C-type natriuretic peptide (Ad.CNP) trans-
duction on the migration of cultured porcine vein fibroblasts. Values
are expressed as the mean percentage ± SEM of migrated cells, as com-
pared with the positive control and Ad.mock, respectively. The negative
control represents fibroblast migration without fetal calf serum (FCS)
stimulation. ∗P = 0.05; ∗∗P = 0.04.
RESULTS
In vitro experiments
First, we examined the efficiency of Ad.CNP transduc-
tion of porcine fibroblasts. Gel electrophoresis of PCR-
amplified products showed clear bands, corresponding to
the size of the murine CNP PCR product (Fig. 2). Three
days after transduction, cGMP production was increased
in Ad.CNP-transduced fibroblasts, when compared to
Ad.mock-transduced fibroblasts (227 ± 22 fmol/mg pro-
tein vs. 123 ± 12 fmol/mg protein, respectively, P = 0.05,
N = 4). The Boyden chamber assay showed that CNP-22
and Ad.CNP transduction, significantly inhibited FCS-
stimulated migration of porcine fibroblast (Fig. 3).
In vivo experiments
Ad.LacZ transduction of porcine veins resulted in
expression of b-galactosidase in the adventitia and, to
lesser extent, in the medial VSMCs, 3 days after gene
transfer (Fig. 4C). As determined by the amount of b-
galactosidase–positive cells in multiple cross-sections of
Ad.LacZ-transduced veins, a viral titer of 1 × 1010 IU/cm
was superior to a titer of 1 × 109 IU/cm (235 ± 75 positive
cells/mm2 vs. 164 ± 17 positive cells/mm2, respectively).
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Fig. 4. Representative Elastin von Gieson–stained 5 lm section of an adenoviral (Ad.mock)-transduced (A) and adreoviral vector encoding
murine C-type natriuretic peptide (Ad.CNP)-transduced (B) vein (original magnification 12.5×). (C) Detail of Ad.LacZ-transduced vein, 3 days
after transduction (original magnification 100×). (D) Detail of a-smooth muscle cell actin–stained section. The dotted line indicated the boundary
of the neointima area (original magnification 200×). The intima predominantly consists of vascular smooth muscle cells (VSMC).
Therefore, a titer of 1 × 1010 IU/cm was used for the
Ad.CNP and Ad.mock transductions.
Three days after in vivo gene transfer of Ad.CNP,
mRNA of murine CNP was detected by RT-PCR
(Fig. 2). Simultaneously, a 56% increase in cGMP con-
tent was observed in tissue extracts of Ad.CNP-treated
vein (N = 2), when compared to Ad.mock-treated veins
(320 and 340 fmol/cm vein vs. 210 and 215 fmol/cm,
respectively).
Two weeks after graft implantation and gene transfer,
all grafts were patent. In none of the pigs, neither sys-
temic nor local side effects of adenoviral transduction
were observed. Flow measurements of the grafted vein
revealed no significant differences between the Ad.CNP
and Ad.mock-transduced veins (900 ± 57 mL/min vs.
808 ± 67 mL/min, respectively, P = 0.2). Histologic anal-
ysis showed that CNP gene transfer did not inhibit in-
timal hyperplasia at the venous anastomosis (Table 1).
Representative sections from the venous anastomosis
are shown in Figure 4. By contrast, the medial area of
Ad.CNP-transduced veins was increased in all pigs, re-
Table 1. Morphometric analysis of Elastin von Gieson–stained
sections obtained from the venous anastomosis
Venous anastomosis Ad.CNP Ad.mock P value
Intima area 2.53 ± 0.9 1.94 ± 0.5 0.53
Medial area 3.1 ± 0.6 1.70 ± 0.3 0.002
Intima/media ratio 0.73 ± 0.1 1.15 ± 0.2 0.034
External elastic lumina 11.8 ± 1.4 9.4 ± 1.0 0.04
Luminal area 10.7 ± 1.4 8.8 ± 1.7 0.05
Ad.CNP is adenoviral vector encoding murine C-type natriuretic peptide.
Intima, media and lumina values are expressed in square millimeters and are the
mean area ± the standard error of the mean (SEM). The exteral elastic lumina
is expressed in millimeters and is the mean length ± the standard error of the
mean (SEM).
sulting in a 37% decrease in intima/media (I/M) ratio,
when compared to Ad.mock-transduced veins. This was
accompanied by an increased circumference of the ve-
nous part of the anastomosis (P = 0.04) and luminal
area of the venous anastomosis in Ad.CNP-treated veins
(P = 0.05). In three out of 12 pigs, the luminal area at
the venous anastomosis was not larger in the Ad.CNP-
transduced veins (nonresponders).
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Proliferation rates and the amount of apoptotic cells
at the venous anastomosis did not differ between
Ad.CNP and Ad.mock-transduced veins (proliferation
rate Ad.CNP 9.8% ± 3% positive cells vs. Ad.mock
10.1% ± 3% positive cells, P = 0.89; apoptotic cells
Ad.CNP 4.3 ± 2 cells per 10 high power fields vs. Ad.mock
5.1 ± 2 cells per 10 high power fields, P = 0.59).
In each graft, one stenotic lesion was observed, with
maximum size at the center of the venous anastomosis.
A continuous decrease in lesion area was observed up to
1 cm away from the anastomosis. At these remote lo-
cations, no significant differences in intimal and medial
areas were observed between the Ad.CNP and Ad.mock-
transduced veins (proximal vein, intimal area Ad.CNP
0.48 ± 0.1 vs. Ad.mock 0.63 ± 0.3, P = 0.94; medial area
Ad.CNP 2.6 ± 0.2 vs. Ad.mock 2.1 ± 0.4, P = 0.18; distal
vein, intimal area Ad.CNP 0.38 ± 0.3 vs. Ad.mock 0.42 ±
0.2, P = 0.87; medial area Ad.CNP 2.7 ± 0.5 vs. Ad.mock
3.0 ± 0.8, P = 0.80).
DISCUSSION
In the present study we show that periadventitial ap-
plication of Ad.CNP in a bilateral arteriovenous ePTFE
graft model is associated with successful transduction, as
demonstrated by the presence of murine CNP-mRNA
and increased cGMP content in the treated vein com-
pared to the mock-transduced contralateral vein. In this
model, local overexpression of CNP results in a signifi-
cant decrease of the I/M ratio compared to the control
vein, predominantly due to increased medial thickening.
Despite the increase in medial thickening of the Ad.CNP
transduced vein, the increase in EEL (i.e., outward re-
modeling) in the Ad.CNP-transduced vein resulted in an
increase of the luminal area at the venous anastomosis of
CNP-treated veins.
The periadventitia as gene therapeutic target
Recent studies have elegantly demonstrated the piv-
otal role of the adventitia, and in particular periadven-
titial fibroblasts in neointima formation and vascular
remodeling. Activated adventitial fibroblasts may infil-
trate the injured media of arterialized vein grafts [19].
Also in a porcine model, Shi et al [20] demonstrated
translocation of adventitial fibroblast to the subendothe-
lial space of vein grafts.
The interest in gene therapeutic approaches in order
to attenuate intimal hyperplasia has multiple rationales.
First, systemic therapies have not been successful in treat-
ing intimal hyperplasia thus far, most likely due to insuffi-
ciently high concentrations of the therapeutic compounds
in the area of interest. In this respect, local adenovirus-
mediated gene therapy offers a promising tool in the
treatment of localized vascular disorders. Second, genes
of interest can be transferred to the adventitia of target
vessels by local transfer, applicable during vascular sur-
gical procedures [21, 22]. In this respect, the paintbrush-
assisted, periadventitial gene delivery technique has been
validated in rabbit and canine carotid arteries [15], result-
ing in targeted and efficient gene transfer with an opti-
mal transduction time of only 10 minutes. In the present
study, we have validated this technique in porcine arteri-
ovenous grafts. Three days after Ad.LacZ transduction,
b-galactosidase–positive cells could be demonstrated in
the adventitia and to lesser extend in the media.
Antimigratory effects of CNP have been shown in hu-
man [23] and rat VSMCs [10]. In order to validate the
biological activity of murine CNP in a porcine model, we
evaluated the effect of CNP on migration of porcine ad-
ventitial fibroblasts. Adenoviral delivery of CNP as well
as CNP-22 showed antimigratory effects on porcine ad-
ventitial fibroblasts. The presence of the NPR-B receptor
on fibroblasts [24] supports the potential of these cells
to respond to CNP stimulation. In addition, CNP is also
secreted from cardiac fibroblasts [25], which are more re-
sponsive to CNP than cardiac smooth muscle cells [26].
Periadventitial delivery of Ad.CNP to porcine veins in
vivo resulted in mRNA synthesis of murine CNP, with a
simultaneous increase in cGMP levels, indicating biolog-
ical activity of CNP.
Effect of adventitial delivery of CNP
CNP significantly decreased the intima to media ra-
tio at the venous outflow tract compared to the mock
transduced contralateral vein. However, CNP did not at-
tenuate initimal hyperplasia in the outflow tract. These
results are consistent with a recent study by Morishige
et al [11], who also showed no effect on intimal hyper-
plasia of adenoviral gene transfer of CNP in a porcine
model of coronary balloon angioplasty. The absence of a
significant decrease of intimal area in vivo, indirectly sug-
gesting “insufficient” inhibition of migration, can be due
to insufficient CNP levels in vivo after adventitial trans-
duction. In contrast, several studies in rabbit [12, 27] and
rat [28] models, have reported suppressed intimal hyper-
plasia after adenoviral gene delivery of CNP. These con-
flicting findings may simply be due to heterogeneity of
the species used in these studies. However, other differ-
ences in the study design may also have contributed to this
apparent discrepancy. In the rat and rabbit studies, aden-
oviral delivery was performed intraluminally. Use of the
latter approach can be expected to result in higher CNP
concentrations compared to the concentration after peri-
adventitial gene delivery, mainly due to the smaller cellu-
lar density in the adventitia. Also, the distance between
the adventitia and subendothelial space may prove to
be a barrier preventing adequate CNP delivery. Of note,
the latter issue was contradicted by previous data in rab-
bits, in which adventitial administration of 10 lmol/L of
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CNP-22 was able to prevent intimal hyperplasia after
carotid artery injury [29].
Notably, we cannot exclude that decreased periadven-
titial Ad.CNP transduction and increased CNP diffusion
distance in pig veins has limited the effect of Ad.CNP
transduction on intimal hyperplasia in the present model.
In contrast to the intimal hyperplasia response, lo-
cal delivery of CNP did result in an increased medial
thickening, which has been associated with vein-graft ar-
terialization [30, 31]. The construction of an arteriove-
nous graft invokes an injury response of medial VSMCs,
characterized by an increase in both apoptosis and
proliferation rates. Overall, these processes determine
successful remodeling of vein grafts during the arterial-
ization phase [32]. The increased medial thickening upon
Ad.CNP transduction can be due to decreased apopto-
sis and/or increased proliferation of medial VSMCs. At
termination 14 days after gene transfer, no significant dif-
ferences between proliferation and apoptosis of VSMCs
could be observed between CNP and mock-transduced
sides. However, the maximum apoptotic and prolifera-
tive rates after vein grafting have been reported to vary
from several hours [33] to 1 week [34]. Therefore, we can-
not exclude that due to the obligatory single time point
observation at 2 weeks we may have missed a significant
effect of CNP on VSMC apoptotic or proliferation rates
at an earlier time point. The exact value of increased
medial thickness in Ad.CNP treated veins is unknown.
Feinfeld et al [35] reported a correlation between media
thickness of the vein at the venous outflow tract and the
number of months undergoing hemodialysis. These struc-
tural adaptations can be expected to enable vein grafts to
withstand high arterial pressure. However, a direct rela-
tion between early medial thickening and long-term graft
patency remains to be established.
Venous outward remodeling is essential for adequate
maturation of the vein distal to the graft. Notably, the lu-
minal area is an important determinant for graft throm-
bosis [1]. Whereas luminal area is determined by wall
thickness and total vessel area, outward remodeling is
defined as an increase in vessel area encompassed by the
EEL. In the present study, a clear increase in luminal area
was observed at the anastomosis of CNP treated veins.
Of note, this increase occurred in spite of a significant in-
crease in media thickness, clearly indicating the presence
of outward remodeling in the Ad.CNP-transduced veins.
These findings concur with previous data, showing de-
creased constrictive remodeling after adenoviral delivery
of CNP in porcine coronary arteries [11]. The mecha-
nism of this effect remains unclear. In comparison, ma-
trix metalloproteinase inhibitors also induce inhibition of
constrictive remodeling in favor of outward remodeling
[36], predominantly due to a decrease in adventitial col-
lagen [37]. Since CNP also inhibits collagen synthesis [25,
38], decreased adventitial collagen accumulation could
have contributed to vascular remodeling upon adventi-
tial CNP overexpression in the present study. In addition,
the increase in luminal area can relate to the antagonistic
effects of natriuretic peptides at various sites in the renin-
angiotensin-aldosterone cascade [39]. Since angiotensin
II has a pivotal role in the process of constrictive remod-
eling [40], inhibition of this system can also contributed
to the beneficial effects on outward remodeling during
CNP overexpression.
The important question whether the increased me-
dial thickening and enhanced outward remodeling after
Ad.CNP transduction will positively affect long-term pa-
tency of the arteriovenous grafts needs to be addressed in
future long-term studies in the present model. In the end,
the potential impact of this finding needs to be validated
in humans.
Study limitations
In the present study, we used an adenoviral vector en-
coding murine CNP. Biochemical properties of murine
CNP might differ from porcine CNP. However, the amino
acid sequence of CNP is identical in human, pig, rat, and
mouse [41, 42]. Furthermore, we have shown production
of biologic active CNP in the present model by measuring
increased levels of cGMP after Ad.CNP transduction in
vivo, as well as by demonstrating antimigratory effect of
murine CNP using porcine fibroblasts in vitro.
Exposure of adenoviral vectors per se has been shown
to induce immunologic and inflammatory reactions,
which can promote the formation of intimal hyperpla-
sia [43]. In the present study, we observed intimal and
medial areas after Ad-mock transduction comparable to
those without adenoviral exposure [17]. Hence, periad-
ventitial paintbrush-assisted adenoviral exposure is un-
likely to contribute to intimal hyperplasia formation in
the present model.
A major limitation of adenoviral gene transfer is the
transient nature of transgene expression, which might ex-
plain the absence of a CNP effect on intimal hyperplasia
in porcine arteriovenous grafts. Significant transgene ex-
pression in grafted jugular veins is maintained for at least
7 days [44]. Other vectors like adeno-associated viruses
might prolong the expression of transferred genes [45].
However, the need for long-term exposure remains to
be established. Thus, a recent study suggested sustained
effects after a single dose of CNP being able to inhibit
intimal hyperplasia in a balloon-injury model in rabbits
[46]. Hence, the effect of long-term CNP exposure in the
present model remains to be evaluated.
CONCLUSION
Periadventitial gene delivery is a feasible approach for
the venous anastomosis of arteriovenous grafts. Local
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overexpression of CNP reduced the I/M ratio and in-
creased the luminal area in the outflow tract of porcine
arteriovenous grafts. These data support the potential of
gene therapeutic strategies in order to attenuate luminal
narrowing at the outflow tract of hemodialysis arteriove-
nous grafts.
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